Latest news with #clinicalstudy
Yahoo
3 days ago
- Business
- Yahoo
Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target
Viatris (VTRS, Financials) shares fell 3.6% on Friday after the firm said that its late-stage clinical study of the blepharitis medication MR-139 did not fulfill its main goal. The study examined pimecrolimus 0.3% ophthalmic ointment on 477 individuals for 12 weeks. Its goal was to get rid of eyelid debris, which is a major sign of blepharitis, but it didn't completely go away after six weeks of is currently thinking about its choices. The company's Chief R&D Officer said that the team might change its plans for future MR-139 trials. Viatris is still hopeful, even though this setback. Its pipeline still contains potential therapies like Tyrvaya and RYZUMVI, and it recently published good findings from two other Phase 3 studies, LYNX-2 and VEGA-3, which were looking at keratorefractive problems and presbyopia, company's long-term plan is still to work on treatments for anterior segment disorders in ophthalmology, and management have said they will keep working on these unmet requirements. This article first appeared on GuruFocus. Sign in to access your portfolio
Globe and Mail
4 days ago
- Business
- Globe and Mail
Pfizer's INLYTA® Study Completion: Real-World Insights and Market Impact
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Pfizer Inc. recently completed a post-marketing surveillance study titled 'Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice.' The study aimed to monitor the dosing adjustments of INLYTA®, a treatment for metastatic renal cell carcinoma (mRCC), in real-world settings. It also assessed the safety profile, objective response rate, and progression-free survival of patients undergoing this treatment. The intervention tested was INLYTA® (axitinib), a medication used to treat mRCC. The primary focus was on understanding how doses are adjusted in routine practice to optimize treatment outcomes. This observational study followed a case-only model with a retrospective time perspective. It did not involve any allocation or masking, as it aimed to observe real-world practices and outcomes. The study began on December 2, 2015, and was completed by July 15, 2025. These dates are crucial as they mark the timeline of data collection and analysis, providing insights into long-term treatment patterns and outcomes. The completion of this study may positively influence Pfizer's stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor confidence. In the competitive landscape of cancer treatments, such updates can enhance Pfizer's market position. The study is completed, and further details are available on the ClinicalTrials portal.
Globe and Mail
4 days ago
- Business
- Globe and Mail
AstraZeneca's Real-Life Study on Benralizumab: Market Implications and Progress
AstraZeneca ((AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Study Overview: AstraZeneca is conducting a non-interventional, prospective study titled A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care Medication in Real-life. The study aims to assess asthma control, health-related quality of life, lung function, and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in Germany. This research is significant as it evaluates real-life outcomes of benralizumab, providing insights into its effectiveness in routine clinical practice. Intervention/Treatment: The study focuses on benralizumab, a monoclonal antibody used to treat severe eosinophilic asthma. It aims to improve asthma control and quality of life by targeting and reducing eosinophils, a type of white blood cell involved in asthma inflammation. Study Design: This is an observational cohort study with a prospective time perspective. It involves a single-arm, multicenter approach where patients' asthma control and quality of life are monitored using various questionnaires and diaries over a 52-week period. Study Timeline: The study began on July 25, 2024, with its primary completion and estimated completion dates yet to be announced. The most recent update was submitted on July 15, 2025. These dates are crucial for tracking the study's progress and anticipating future findings. Market Implications: The ongoing study could influence AstraZeneca's stock performance by showcasing benralizumab's real-world effectiveness, potentially boosting investor confidence. As the asthma treatment market is competitive, positive results may enhance AstraZeneca's position against competitors, impacting market dynamics and investor sentiment. The study is currently recruiting, with further details available on the ClinicalTrials portal.
Irish Times
7 days ago
- Health
- Irish Times
Hidden benefits of the Irish diet: How strawberries, black tea and potatoes can boost your health
When it comes to superfoods, we often think they come from far-flung and exotic places. But traditional Irish foods can pack a health punch, giving our innate health defences a boost. Carrots Lots of Irish children grow up hearing a myth that eating carrots will help them to see in the dark, but it's grown-ups who benefit the most. Carrots are rich in carotenoids that protect our eye health from vision loss as we age . Other benefits include lowering lipids; a clinical study of healthy adults showed eating the equivalent of four medium carrots a day for three weeks lowered cholesterol by 11 per cent . Another study from the UK, involving 64 volunteers, indicated cooked carrots may also support repair mechanisms for DNA damage which may be a result of exposure to environmental toxins or UV radiation from the sun. Cabbage When it comes to health, cabbage is anything but bland. Like other cruciferous vegetables, it is packed with isothiocyanates which lower inflammation and have cancer fighting activity. One study of 345,000 people found that eating half a cup (60g) of shredded cabbage a day was associated with a 44 per cent lower risk of developing cancer of the head and neck. When you pickle the cabbage, it becomes a probiotic food that boosts gut health. Eating half a cup of shredded cabbage a day was associated with a lower risk of developing cancer of the head and neck, one study found. Photograph: Brendan Hoffman/The New York Times Oats Many of us are rightly committed to a bowl of porridge to start the day. Oats are loaded with beta-D-glucan, a type of fibre that lowers inflammation and improves gut health , including helping us grow a good bacterium called akkermansia that benefits metabolism and may help people respond better to some forms of cancer treatment . Another substance in oats called avenanthramide has strong anti-inflammatory activity in humans. READ MORE White button mushrooms A traditional full Irish breakfast would not be complete without mushrooms. Their flesh contains beta-glucan (like oats) and polysaccharides that support brain health. A clinical study of 2,840 older adults showed mushroom eaters had better cognitive performance, even with as little as one third of a cup (22g) a day . Increase that to three cups (240g) a week, and another observational study of 600 over-60s showed a 50 per cent reduction in cognitive decline. And guess what? The mushroom stem has twice as much power as the cap. [ What to do when you've had a poor night's sleep ] Apples There's some scientific backing for the age-old claim that an apple a day keeps the doctor away. Baked, stewed, eaten fresh or pressed for cider, apple flesh contains chlorogenic acid, which improves your body's fat-burning ability. Eating one or two apples a day was found in an epidemiological study to be associated with a reduced risk of colon, breast, lung, bladder and prostate cancers . Even the peel is beneficial. It contains pectin, used to make jam, which is a prebiotic that's good for gut health. It also contains ursolic acid, which can stimulate stem cells to help the body regenerate and heal. Eating two cups of strawberries a day may improve memory and decrease depression. Photograph: Nick Bradshaw Strawberries Ireland's annual strawberry crop is more than 8,000 tonnes every year. Their delicious tartness comes from ellagic acid, which has been shown to potentially have a role in starving cancer by cutting off its blood supply and it helps your immune system destroy cancer cells. Strawberries may also benefit brain health. A small clinical study of 30 people showed eating the equivalent of two cups (332g) of strawberries a day may improve memory and decrease depression. Another study showed one cup of berries was associated with a 34 per cent reduction in risk for Alzheimer's disease . When the summer fades, frozen strawberries deliver the same benefits; and the autumn crop of blackberries will also give you a dose of antioxidant and anti-inflammatory compounds. Oysters Ireland's coastline produces marvellous briny oysters. Like many seafoods, they contain omega-3 fats, which are well known to improve heart, brain and metabolic health. Oyster meat contains high amounts of the amino acid taurine, which has protective antioxidant effects to counter DNA damage which, left unchecked, might go on to become cancerous. If raw oysters aren't your thing then eating them baked is a delicious option. Oysters are good for the brain and heart. Photograph: Alan Betson Black tea Irish breakfast tea is a blend of black teas. While the benefits of green tea are widely accepted, black tea also contains polyphenols that support all of our body's defence systems. It can improve circulation, protect DNA, improve gut health and, according to one intriguing but small scale study involving 19 patients , it may even mobilise stem cells which are critical for ongoing regenerative processes within the body. To avoid ingesting microplastics that tea bags can shed, make your cuppa with loose leaf tea. Potatoes, cheese ... and beer? While they are not recommended as part of a healthy diet, researchers are uncovering the surprisingly beneficial properties of potatoes, cheese and even beer. Because cheese is a fermented food, it is probiotic and can contribute beneficial bacteria to the gut. But you'll need to watch out for the high salt content and saturated fat. Potatoes contain a peptide discovered in the lab to protect the kidney and liver, and even lower inflammation in the brain of mice though not yet in humans. Unfortunately this is not a licence to devour chips fried in unhealthy oils or mash laden with butter. And the hops in beer contain a polyphenol called xanthohumol thought to have anti-diabetes, anti-inflammatory, and cancer-starving effects. Note the benefits come from the hops, not the alcohol itself, and even then you'd need to consume a lot of hops to get the benefits. In Ireland, as elsewhere, traditional foods are central to our culture and cooking. It should give us a huge sense of relief and joy that many everyday recipes passed through the generations include ingredients that are common, affordable, delicious – and healthy. Dr Ruth Freeman is director of Research for Society at Taighde Éireann/Research Ireland. Dr William Li is president and medical director of the Angiogenesis Foundation and is author of Eat to Beat Disease
Yahoo
14-07-2025
- Business
- Yahoo
Adia Nutrition Inc. Celebrates Grand Opening of Adia Med of San Antonio, First Licensed Clinic, Led by Michele DeLeon MD
Winter Park, Florida--(Newsfile Corp. - July 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine, proudly announces the grand opening of Adia Med of San Antonio, its first licensed clinic under a strategic license agreement, located at 18707 Hardy Oak Blvd, Suite 500, San Antonio, Texas 78258. Headed by esteemed wellness regenerative expert Michele DeLeon MD, this cutting-edge facility marks a significant step in expanding access to innovative regenerative therapies across the United States. Adia Med of San Antonio will offer FDA-registered products, including AdiaVita The Most Trusted Brand (umbilical cord stem cells with 100 million viable cells and 3 trillion exosomes per unit) and AdiaLink (3.5 trillion exosomes per unit). Additionally, Adia Med of San Antonio will collaborate with Adia Med of Winter Park in a groundbreaking clinical study exploring regenerative therapies for autism, further advancing the company's commitment to transformative healthcare solutions. "We are thrilled to launch Adia Med of San Antonio as our first licensed clinic, under the exceptional leadership of Michele DeLeon MD," said Larry Powalisz, CEO of Adia Nutrition Inc. "This vibrant new location, combined with clinical study for autism alongside Adia Med of Winter Park, is a testament to our unwavering commitment to transforming lives through cutting-edge care. San Antonio is just the beginning of an exciting new chapter for Adia Nutrition." "Equipped with state-of-the-art technology and staffed by a highly trained team, Adia Med of San Antonio upholds the rigorous standards of Adia Nutrition's existing clinics, including Adia Med Winter Park. For those interested in licensing Adia Med's name and becoming part of its innovative network, please reach out to ceo@ or call 321-788-0850 for more information. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
